The Drug Enforcement Administration received 38,000 comments on its proposed rule that would roll back Covid-19 flexibilities for the prescribing of controlled substances via telemedicine. In response, the DEA chose to temporarily extend the flexibilities, a decision telehealth companies like Bicycle Health and Mindbloom are in support of.
The DEA recently released proposed rules that would require an in-person visit before a patient can receive a telehealth prescription for a controlled substance. The DEA touts the change as a way to ensure patient safety, but several telehealth advocates argue it will greatly disrupt access for those who need the drugs — especially at a time when the mental health and substance use crisis is growing.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Electronic prescribing of controlled substances (EPCS) is finally gaining momentum, but there are common misconceptions.
Everyone agrees patients are waiting far too long to access new drugs and treatments that enhance and extend lives. Most people concerned with accelerating treatments and cures are understandably focused on the process of drug discovery, development and approval. However, a less known but equally frustrating impediment is a federally required “scheduling” under the Controlled […]